Acute Oxalate Nephropathy Associated With Orlistat, a Gastrointestinal Lipase Inhibitor

American Journal of Kidney Diseases

Volumn 49, Issue 1, 2007, Pages 153-157

  Singh, Ashutosh ^a   Sarkar, Shubho R ^a   Gaber, Lillian W ^a   Perazella, Mark A ^a  

^a Nephrology Consultants   (United States)

Author keywords

Acute kidney injury; acute oxalate nephropathy; crystalluria; orlistat

Indexed keywords

ALPRAZOLAM; CALCITRIOL; CALCIUM OXALATE; COLCHICINE; DILTIAZEM; FUROSEMIDE; GLIMEPIRIDE; IPRATROPIUM BROMIDE; LEVOTHYROXINE; MONTELUKAST; PANTOPRAZOLE; PAROXETINE; SALBUTAMOL; TETRAHYDROLIPSTATIN;

ADULT; ARTICLE; ASTHMA; CASE REPORT; CHRONIC KIDNEY DISEASE; CLINICAL FEATURE; DRUG DOSE INCREASE; DRUG EFFECT; DRUG WITHDRAWAL; EVALUATION; FEMALE; FLUID INTAKE; FOLLOW UP; GASTROESOPHAGEAL REFLUX; GENERAL CONDITION IMPROVEMENT; GOUT; HUMAN; HUMAN TISSUE; HYPERTENSION; HYPOTHYROIDISM; KIDNEY BIOPSY; KIDNEY INJURY; KIDNEY TUBULE; LIPID ABSORPTION; LOOSE FECES; MALAISE; NON INSULIN DEPENDENT DIABETES MELLITUS; OXALIC ACID NEPHROPATHY; STEATORRHEA; SYMPTOM; URINE LEVEL; URINE SEDIMENT; WEAKNESS;

ACUTE DISEASE; CALCIUM OXALATE; ENZYME INHIBITORS; FEMALE; HUMANS; KIDNEY DISEASES; LACTONES; LIPASE; MIDDLE AGED;

EID: 33845591394     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.ajkd.2006.10.004     Document Type: Article

References (16)

1. Perazella M.A. Crystal-induced acute renal failure. Am J Med 106 (1999) 459-465
2. Stokes M.B. Acute oxalate nephropathy due to ethylene glycol ingestion. Kidney Int 69 (2006) 203
3. Keiran S., Bhimani B., and Dixit A. Ethylene glycol toxicity. Am J Kidney Dis 46 (2005) e31-e33
4. Winearls C.G. Iatrogenic acute oxalate nephropathy. Nephrol Dial Transplant 10 (1995) 2171
5. Chen C.L., Fang H.C., Chou K.J., Wang J.S., and Chung H.M. Acute oxalate nephropathy after ingestion of star fruit. Am J Kidney Dis 37 (2001) 418-422
6. Hill P., Karim M., Davies D.R., Roberts I.S.D., and Winearls C.G. Rapidly progressive irreversible renal failure in patients with pancreatic insufficiency. Am J Kidney Dis 42 (2003) 842-845
7. Ferraz R.R., Tiselius H.G., and Heilberg I.P. Fat malabsorption induced by gastrointestinal lipase inhibitor leads to an increase in urinary oxalate excretion. Kidney Int 66 (2004) 676-682
8. Weibel E.K., Hadvary P., Hochuli E., et al. Lipstatin, an inhibitor of pancreatic lipase produced by Streptomyces toxytricini. Producing organism, fermentation, isolation and biological activity. J Antibiot 40 (1987) 1081-1085
9. Davidson M.H., Hauptman J., DiGirolamo M., et al. Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: A randomized controlled trial. JAMA 281 (1999) 235-242
10. Rossner S., Sjostrom L., Noack R., Meinders A.E., and Noseda G. Weight loss, weight maintenance, and improved cardiovascular risk factors after 2 years treatment with orlistat for obesity. European Orlistat Obesity Study Group. Obes Res 8 (2000) 49-61
11. Hollander P.A., Elbein S.C., Hirsch I.B., et al. Role of orlistat in the treatment of obese patients with type 2 diabetes. A 1-year randomized double-blind study. Diabetes Care 21 (1998) 1288-1294
12. Miles J.M., Leiter L., Hollander P., et al. Effect of orlistat in overweight and obese patients with type 2 diabetes treated with metformin. Diabetes Care 25 (2002) 1123-1128
13. Padwal R., Li S.K., and Lau D.C. Long-term pharmacotherapy for obesity and overweight. Cochrane Database Syst Rev (2004) CD004094 (CD ROM)
14. Jaeger P., and Robertson W.G. Role of dietary intake and intestinal absorption of oxalate in calcium stone formation. Nephron Physiol 98 (2004) 64-71
15. Nelson W.K., Houghton S.G., Milliner D.S., Lieske J.C., and Sarr M.G. Enteric hyperoxaluria, nephrolithiasis, and oxalate nephropathy: Potentially serious and unappreciated complications of Roux-en-Y gastric bypass. Surg Obes Relat Dis 1 (2005) 481-485
16. Evans S., Robson M., Wells H., et al. Drug interaction in a renal transplant patient: Cyclosporin-Neoral and orlistat. Am J Kidney Dis 41 (2003) 493-496